Search

Search Constraints

You searched for: Author/Creator Travis, Simon

Search Results

1. A Treat to Target Approach Decreases the Rate of CD‐Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM2017 ACG Governors Award for Excellence in Clinical Research: 598. (October 2017)

2. Adalimumab Therapy Achieves Clinical Remission and Response at Week 26 in Chinese Patients With Crohn's Disease: 1874. (October 2015)

3. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Issue 11 (14th October 2010)

4. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (18th September 2020)

5. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Issue 10 (27th February 2020)

9. COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS. (22nd January 2022)

10. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. (16th March 2018)